REG - Alliance Pharma PLC - Block Listing Six Monthly Return

Alliance PharmaAnnouncement

29/12/2021 09:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211229:nRSc9410Wa&default-theme=true

RNS Number : 9410W  Alliance Pharma PLC  29 December 2021

 

 For immediate release  29 December 2021

 

 

 

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

 

Block Listing Six Monthly Return

 

 Name of applicant:                                                              ALLIANCE PHARMA PLC
 Names of schemes:                                                               a)     The Alliance Pharma plc Approved Share Option Plan 2005

                                                                                 b)    The Alliance Pharma plc Share Option Plan 2006

                                                                                 c)     The Alliance Pharma plc Company Share Option Plan 2015
 Period of return:                       From:                                   28 June 2021             To:                      28 December 2021
 Number of securities originally admitted at date of admission:                  25,000,000 ordinary shares of 1p each

                                                                                 28 June 2017
 Balance of unallotted securities under schemes from previous return:            a)     35,320

                                                                                 b)    4,948,713

                                                                                 c)     11,449,557
 Plus:  The amount by which the block schemes have been increased since the      a)     Nil
 date of the last return (if any increase has been applied for):

                                                                                 b)    Nil

                                                                                 c)     Nil
 Less:  Number of securities issued/allotted under schemes during period:        a)  16,702

                                                                                 b) 1,856,932

                                                                                 c)  1,049,914

 Equals:  Balance under schemes not yet issued/allotted at end of period:        d)    18,618

                                                                                 e)     3,091,781

                                                                                 f)     10,399,643

 

 Name of contact:              Chris Chrysanthou, Company Secretary
 Telephone number of contact:  Tel. +44 (0)1249 705166

 

 

For further information:

 

 Alliance Pharma plc                                     + 44 (0)1249 466966
 Peter Butterfield, Chief Executive Officer
 Andrew Franklin, Chief Financial Officer
 www.alliancepharma.co.uk
 Buchanan                                                + 44 (0)20 7466 5000
 Mark Court / Sophie Wills / Hannah Ratcliff

 Numis Securities Limited                                + 44 (0)20 7260 1000
 Nominated Adviser: Freddie Barnfield / Duncan Monteith
 Corporate Broking: James Black

 

 Investec Bank plc                + 44 (0) 20 7597 5970
 Corporate Finance: Daniel Adams
 Corporate Broking: Patrick Robb

 

About Alliance

Alliance Pharma plc (AIM: APH) is an international healthcare group. Our
purpose is to improve the lives of consumers and patients through making
available a range of clinically valuable healthcare products.

Our core focus is on the marketing of Consumer Healthcare brands, complemented
by a smaller Prescription Medicines business. In total, we hold marketing
rights to around 80 brands, with revenues generated from a mix of direct,
distributor and e-commerce sales.

Headquartered in the UK, the Group employs around 250 people based in
locations across Europe, North America, and the Asia Pacific region. By
outsourcing our manufacturing and logistics operations, we remain asset-light
and focused on maximising the value of our brands.

For more information on Alliance, please visit our website:
www.alliancepharmaceuticals.com (http://www.alliancepharmaceuticals.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BLRUKUKRAVUUURA